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Abstract
 .MARCKS myristoylated alanine-r ich C-k inase substrate is known to interact with calmodulin, actin filaments, and
 .anionic phospholipids at a central basic domain which is also the site of phosphorylation by protein kinase C PKC . In the
 .present study, cytochalasin D CD and calmodulin antagonists were used to examine the influence of F-actin and
calmodulin on membrane interaction of MARCKS in C6 glioma cells. CD treatment for 1 h disrupted F-actin filaments,
 .increased membrane bound immunoreactive MARCKS from 51% to 62% of total , yet markedly enhanced the amount of
MARCKS translocated to the cytosolic fraction in response to the phorbol ester 4b-12-O-tetradecanoylphorbol 13-acetate.
In contrast, CD treatment had no effect on phorbol ester-stimulated phosphorylation of MARCKS or on translocation of
PKCa to the membrane fraction. Staurosporine also increased membrane association of MARCKS in a PKC-independent
 .manner, as no change in MARCKS phosphorylation was noted and bis-indolylmaleimide a more specific PKC inhibitor
did not alter MARCKS distribution. Staurosporine inhibited the phorbol ester-induced translocation of MARCKS but not of
 .PKCa in both CD pretreated and untreated cells. Calmodulin antagonists trifluoperazine, calmidazolium had little effect
on the cellular distribution or phosphorylation of MARCKS, but were synergistic with phorbol ester in translocating
MARCKS from the membrane without a further increase in its phosphorylation. We conclude that cytoskeletal integrity is
not required for phosphorylation and translocation of MARCKS in response to activated PKC, but that interaction with both
F-actin and calmodulin might serve to independently modulate PKC-regulated localization and function of MARCKS at
cellular membranes.
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1. Introduction
 .Activation of protein kinase C PKC by receptor-
mediated phospholipid hydrolysis plays an important
role in regulation of a variety of cellular processes,
including proliferation, differentiation, and secretion
w x1–4 . In many cell types, one of the earliest and
most abundant proteins phosphorylated in response to
PKC activation is MARCKS m yristoylated
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.alanine-r ich C-k inase substrate , a 28–32 kDa acidic
heat-stable protein which migrates anomalously as a
w x70–80 kDa band on SDS-PAGE 5–7 . MARCKS
contains a central basic effector domain which inter-
w xacts with membrane phospholipids 8–10 , calmod-
w x w xulin 11–13 , and actin 14 ; phosphorylation by PKC
of up to four serine residues in this domain has been
shown to inhibit all of the above interactions. Al-
though the physiological function of MARCKS has
not been established, competition for the effector
domain is thought to be central to proposed roles for
MARCKS in Ca2qrcalmodulin and PKC-mediated
membrane-cytoskeletal alterations accompanying cell
w xmigration and motility 15,16 and vesicle trafficking
w x17,18 .
The localization and interactions of MARCKS at
the membrane is undoubtedly essential to its function.
MARCKS has been co-localized with vinculin and
w xtalin at focal adhesion sites 16 and with phagosomes
w x18 in macrophages, and activation of PKC results in
reversible translocation of the protein from the mem-
w xbrane to the cytosol 16,19,20 . More recent investi-
gations have indicated that interaction of MARCKS
with membranes requires both a hydrophobic contri-
bution from the N-terminal myristate moiety and
electrostatic interaction between the central basic do-
w xmain and acidic phospholipids 9,10,21–23 . Phos-
phorylation of, or calmodulin binding to, the basic
domain was shown to negatively affect the latter
interaction. However, a clear relationship between
MARCKS phosphorylation and its translocation has
w xnot been observed in several other studies 24–26 ,
suggesting that other cellular components such as the
cytoskeleton might influence the membrane localiza-
tion of MARCKS.
While interactions of MARCKS with calmodulin,
PKC, and membrane lipids have received consider-
able attention, relatively little is known about the
effect of F-actin binding on the localization and
properties of MARCKS. MARCKS could provide a
reversible cross-link between membrane lipids and
actin filaments or, conversely, F-actin might help
tether MARCKS to the membrane, perhaps via addi-
tional PKC-sensitive actin binding proteins. The pres-
ent investigation addresses these interactions using
digitonin-permeabilized glioma cells to assess mem-
brane affinity of MARCKS under a variety of condi-
tions. Our results are consistent with a model in
which F-actin and calmodulin may act to modulate
MARCKS localization in response to PKC activation.
2. Materials and methods
2.1. Materials
w32 x wCarrier-free P orthophosphoric acid and 9,10-
3 x  .H myristic acid 11 Cirmmol were purchased from
DuPont Canada NEN Products, Lachine, PQ,
.  .Canada . Triton X-100 Surfact-Amps and Micro-bi-
cinchoninic protein assay kits were from Pierce
Chromatographic Specialties, Brockville, Ont.,
.Canada . Digitonin, 4b-12-O-tetradecanoylphorbol
 .13-acetate TPA , cytochalasins B and D, phalloidin,
 .  .staurosporine STS , saponin, trifluoperazine TFP ,
protease inhibitors and lactate dehydrogenase kit were
purchased from Sigma Chemical Co. St. Louis, MO,
.  .USA . Bis-indolylmaleimide BIM, GF 109203X and
calmidazolium hydrochloride were obtained from
 .Calbiochem San Diego, CA, USA . Equipment and
reagents for sodium dodecyl sulfate-polyacrylamide
 .gel electrophoresis SDS-PAGE and Western blot-
ting were from BioRad Canada Mississauga, Ont.,
.Canada , while enhanced chemiluminescence detec-
 .tion ECL kits and Hyperfilm MP were from Amer-
 .sham Canada Oakville, Ont., Canada . Affinity puri-
fied polyclonal anti-PKCa antibody directed against
a synthetic peptide corresponding to amino acids
313-326 of rat PKCa was purchased from Gibco
 .BRL Life Technologies, Burlington, Ont., Canada .
Fluorescein phalloidin was obtained from Molecular
 .Probes Eugene, OR, USA .
2.2. Cell culture and labelling
 .C6 rat glioma cells CCL-107 were maintained in
150-cm2 flasks containing 45 ml of Dulbecco’s mod-
ified Eagle’s medium with 10% fetal bovine serum
 . w xFBS as described previously 27 . For most experi-
ments, 7=105 cells were seeded into 35 mm dishes
and grown 5 days at 378C in a humidified atmosphere
of 95% air and 5% CO . Protein phosphorylation2
experiments were performed by incubation with 20
w32 xmCi of P P in 1 ml of phosphate-free mediumi
supplemented with 10% dialyzed FBS for 4 h. Cy-
 .tochalasin D 10 mM final concentration was added
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 .for the final hour of labelling, while TPA 200 nM ,
 .  . BIM 10 mM , STS 200 nM , calmidazolium 1
.  .mM , andror TFP 50 mM were added 15 min prior
 .to extraction. In some experiments not shown pro-
w3 xteins and lipids were labelled with H myristic acid
 .by overnight incubation 50 mCirml prior to treat-
w xment 26 . Control dishes received equivalent vol-
umes of dimethyl sulfoxide carrier alone; the final
 .concentration of carrier never exceeded 0.3% vrv .
2.3. Subcellular fractionation
After washing cells twice with 2 ml Na-Hepes
buffer 15 mM Hepes, 140 mM NaCl, 1.2 mM
KH PO , 4.7 mM KCl, 1 mM MgCl , 5.5 mM2 4 2
.glucose, pH 7.4 , cytosolic and membrane proteins
were separated by sequential extraction with digi-
tonin and Triton X-100. Cells were permeabilized
with 100 mM digitonin in K-Hepes buffer 15 mM
Hepes, 115 mM KCl, 1.2 mM KH PO , 1 mM2 4
MgCl , 1 mM EGTA, 10 mM KF, 5 mM Na P O ,2 4 2 7
5.5 mM glucose, 1 mM leupeptin, 200 mM phenyl-
.methylsulfonyl fluoride, pH 7.0 by incubation on a
 .rotary shaker 70 rpm for 10 min at 258C. After
removal of the soluble cytosolic fraction, membrane
proteins were extracted from the dish using 1 ml of
 .K-Hepes buffer containing 1% vrv Triton X-100
instead of digitonin. In some experiments, the insolu-
ble cytoskeletalrnuclear fraction remaining on the
dish was harvested by scraping in K-Hepes buffer
and boiled directly in SDS-PAGE sample buffer. The
resulting digitonin, Triton X-100-soluble and Triton
X-100-insoluble fractions contained respectively 35%,
50%, and 15% of total cell protein, and 4%, 92%,
w3 x and 4% of total H myristic acid label mainly in
.phospholipid . These proportions did not vary with
the different treatments used, thus equivalent volumes
 .were used for SDS-PAGE analysis below . Digi-
tonin-induced permeabilization was assessed by lac-
 . Xtate dehydrogenase EC 1.1.1.27 and 5 -nucleotidase
 .EC 3.1.3.5 release as cytosolic and plasma mem-
w xbrane marker enzymes, respectively 28 .
2.4. SDS-PAGE and protein analysis
Samples were prepared for Western blot analysis
 .either directly from cell extracts for PKCa or
 .following heat treatment 808C for 10 min as out-
w xlined previously for MARCKS 29 . Proteins in each
fraction were precipitated by incubation with 5 vol-
umes of cold acetone for at least 2 h at y208C.
Precipitated proteins were centrifuged, dissolved in
SDS sample buffer, and separated by SDS-PAGE
 . w x10% acrylamide, 100 V 30 . After electrophoretic
 .transfer, nitrocellulose membranes 0.45 mm were
 .blocked with 5% wrv non-fat dry milk in TBS-
Tween buffer 25 mM Tris-HCl, pH 7.5, 125 mM
.NaCl, 0.1% Tween 20 for at least 1 h, then incu-
bated with the appropriate primary antibody for 1 h at
room temperature. MARCKS was detected using rab-
bit anti-rat MARCKS peptide antisera C-terminal
w x.epitope SPEAPPAPVAE 29 at 1:1000 dilution in
TBS-Tween buffer. For PKCa detection, rabbit anti-
PKCa-antibody was diluted to 2 mgrml in TBS-
Tween buffer. After incubation with primary anti-
body, membranes were incubated 1 h at room tem-
perature with a 1:10 000 dilution of goat ant-rabbit
IgG conjugated to horse radish peroxidase and im-
munoreactive bands were visualized by ECL. MAR-
CKS was enriched in 32Pi-labelled cell extracts by
heating as above. After removal of denatured proteins
by centrifugation, heat-stable proteins were precipi-
 .tated by addition of 2.5 vol of 20% wrv trichloro-
acetic acid for at least 2 h on ice. 32Pi-labelled
proteins were visualized by autoradiography.
Radioactive or immunoreactive proteins were
quantified by densitometric scanning using an Apple
OneScanner with Ofoto software Light Source, Inc.,
.Greenbrae, CA, USA , followed by analysis with
NIH Image version 1.49 software Research Services
.Branch, NIH, Bethesda, MD, USA . The amount of
MARCKS or PKCa in each fraction was expressed
as a percentage of the total from that dish; this total
did not change significantly as a result of the short
term treatments used in this study. During the course
of this investigation, no significant amount of
MARCKS was detected in the Triton-insoluble cyto-
 .skeletal fraction data not shown .
2.5. Fluorescence microscopy
Cell cultures grown on glass coverslips were sub-
jected to the same treatments as outlined above,
followed by two washes in PBS 140 mM NaCl, 3
mM KCl, 10 mM Na HPO and 2 mM KH PO , pH2 4 2 4
.7.4 . Cells were subsequently fixed in 3.7% formal-
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dehyde in PBS for 10 min followed by two more
washes in PBS. The coverslips were then extracted
with acetone at y208C for 3 to 5 min and air dried.
F-actin was labelled by 25 min incubation with 1 unit
of fluorescein-phalloidin diluted in 200 ml PBS. La-
belled coverslip cultures were washed twice rapidly
with excess PBS and mounted on a 1:1 solution of
PBS and glycerol. Samples were observed and photo-
graphed with an Olympus fluorescence microscope.
3. Results
3.1. Cytochalasin D and staurosporine alter
MARCKS localization and translocation in response
to phorbol ester
To study interaction of MARCKS with the mem-
brane in a permeabilized cell system, conditions re-
quired to selectively extract cytosolic and
membrane-bound proteins were optimized in C6
glioma cells. Incubation with either digitonin Fig.
.  .1A or saponin Fig. 1B resulted in time- and con-
centration-dependent release of a cytosolic marker
 .protein lactate dehydrogenase into the medium.
 .Streptolysin-O permeabilization 2 IUrml resulted
in only 50% release of the enzyme under similar
 .conditions data not shown . Incubation of cells for
10 min with 100 mM digitonin released 81"2%
 .ns3 of total lactate dehydrogenase activity, but
X only 8.0"0.6% of total 5 -nucleotidase activity a
.plasma membrane marker , and was thus chosen for
further studies.
Given the ability of MARCKS to cross-link F-actin
w x14 and co-localize with both vinculin and talin at
focal adhesion sites where actin stress fibers termi-
w xnate at the plasma membrane 16 , we examined
whether the integrity of the actin cytoskeleton influ-
ences either the affinity of MARCKS with the mem-
brane or its response to activated PKC. C6 glioma
cells were pretreated for 1 h with increasing concen-
 .trations of cytochalasin D CD , an agent that selec-
tively disrupts microfilaments, and actin was visual-
ized with fluorescein-phalloidin staining. CD pre-
treatment resulted in a dose-dependent loss of fila-
mentous actin networks seen spanning the cytoplasm,
with complete cytoskeletal disruption seen at 10 mM
 .CD Fig. 2 .
Fig. 1. Release of a cytosolic marker protein lactate dehydroge-
.nase from glioma cells by digitonin and saponin permeabiliza-
tion. C6 glioma cells grown 5 days in 35 mm dishes were washed
 .with Na-Hepes buffer see text and incubated at 258C with the
 .indicated concentrations of either digitonin panel A or saponin
 .  .panel B in K-Hepes buffer 1 ml for the times shown. Dishes
were then incubated with K-Hepes buffer containing Triton X-100
and lactate dehydrogenase activity was measured in both frac-
tions; total activity was constant in all samples. Data are ex-
pressed as percent of total activity released by digitonin or
saponin; the mean and S.D. of three samples are shown.
Cytochalasin D treatment resulted in a significant
increase in the proportion of immunoreactive MAR-
CKS associated with the membrane fraction of C6
glioma cells, with a reciprocal decrease in the cytoso-
lic fraction. A representative experiment is shown in
 .Fig. 3 upper panel ; densitometric evaluation of data
from several experiments indicated that membrane
MARCKS increased from 51"5% to 62"2% of
 .total MARCKS after CD treatment Table 1 . The
increased membrane association of MARCKS in the
presence of CD actually enhanced its subsequent
translocation to the cytosol upon activation of PKC:
addition of 200 nM TPA decreased the proportion of
membrane MARCKS to 35"1% in CD treated cells
 .vs 42"3% in TPA-treated control cells . Thus, the
amount of MARCKS translocated from membrane to
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Fig. 2. Disruption of F-actin filaments in cytochalasin D-treated C6 glioma cells. Cells incubated in the absence or presence of 10 mM
CD for 1 h were stained with fluorescein-phalloidin prior to fluorescence microscopy.
cytosol by TPA was almost three-fold greater in
CD-treated than in untreated cells. Similar results
were also observed when MARCKS was visualized
w3 xby H myristate-labelling or when F-actin was dis-
rupted with cytochalasin B, while stabilization of
F-actin filaments by phalloidin was without effect on
 .MARCKS distribution data not shown . From these
observations, we conclude that disruption of F-actin
in C6 cells increases the membrane affinity of MAR-
CKS, yet renders it more sensitive to TPA-induced
translocation to the cytosol.
The non-specific PKC inhibitor STS also increased
membrane association of MARCKS to the level seen
in CD-treated cells; however, unlike CD, STS antag-
onized rather than enhanced TPA-induced transloca-
 .tion to the cytosol Fig. 3 and Table 1 . Addition of
both STS and CD to cells produced no greater mem-
brane association of MARCKS than either reagent
alone, but completely blocked any effect of TPA on
MARCKS translocation. In a separate experiment, 10
 .mM bis-indolylmaleimide BIM did not appreciably
alter MARCKS localization 47"3% vs 49"2%
membrane associated in BIM-treated vs untreated
.cells . As BIM is a much more specific inhibitor of
w xPKC 31 , which completely blocks PKC activity at
w xthis concentration in C6 cells 32 , these data suggest
Fig. 3. Effects of TPA and staurosporine on the distribution of MARCKS and PKCa in control and cytochalasin D-treated C6 glioma
 .  .cells. Confluent cell cultures were exposed to either cytochalasin D 10 mM or an equivalent volume of carrier 0.1% vrv for 1 h. For
 .the final 15 min of incubation, dishes were treated with 200 nM TPA and 200 nM STS " as indicated . Soluble and membrane proteins
were obtained by sequential extraction with digitonin followed by Triton X-100, separated by SDS-PAGE, immunoblotted and probed
 .  .with anti-MARCKS upper panel or anti-PKCa lower panel antibodies, then visualized by ECL detection.
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Table 1
Effects of cytochalasin D, phorbol ester, and staurosporine on membrane association of MARCKS and PKCa in C6 glioma cells. Cells
 .  . were treated as outlined in ‘Experimental Procedures’ with CD 10 mM for 1 h , TPA 200 nM for 15 min andror STS 200 nM for 15
.min as indicated prior to digitonin permeabilization. Proteins from soluble and membrane fractions were separated by SDS-PAGE and
 .analyzed by Western blotting for MARCKS and PKCa a representative experiment is shown in Fig. 3 . The amount of MARCKS or
PKCa was determined by densitometric analysis and the membrane content expressed as a percentage of the total amount from that dish.
The mean"S.E.M. for the membrane fractions from 3–6 separate dishes
 .Treatments Membrane association % of total
CD TPA STS MARCKS PKCa
y y y 51"5 39"2
ay q y 42"3 87"3
y q q 51"6 87"2
by y q 67"2 44"3
cq y y 62"2 44"4
aq q y 35"1 84"4
q q q 67"5 89"4
q y q 68"2 41"1
a  .Significantly P-0.05 different from corresponding -TPA control in Student’s t-test.
b  .Significantly P-0.005 different from corresponding -STS control.
c  .Significantly P-0.025 different from corresponding -CD control.
that CD and STS might act similarly to enhance
membrane association of MARCKS in a PKC-inde-
pendent manner.
3.2. Cytochalasin D and staurosporine do not influ-
ence MARCKS localization by altered phosphoryla-
tion of the protein
To determine which of the above effects on mem-
brane association of MARCKS might be due to
changes in basal or TPA-stimulated phosphorylation
of the protein, MARCKS labelled in vivo with 32Pi
was partially purified by heat treatment and analyzed
 .by SDS-PAGE and autoradiography Fig. 4 . MAR-
CKS was identified as the 80 kDa phosphorylated
w xband on the basis of its selective heat stability 33
and earlier 2D-PAGE analysis of proteins phosphory-
w xlated in response to TPA in C6 cells 26 . As noted in
the latter study, TPA treatment stimulated MARCKS
phosphorylation in both soluble and membrane frac-
tions, but CD had no effect on either the basal
phosphorylation of MARCKS or the degree of stimu-
lation produced by TPA phosphorylation of total
cellular MARCKS was increased 4.5"0.7 and 4.5"
1.5 fold by TPA in the absence and presence of 10
.mM CD, respectively, in three experiments . STS
completely blocked the TPA-induced phosphoryla-
 .tion of MARCKS not shown , but when added alone
did not decrease basal levels of MARCKS phospho-
 .rylation below that of control cells Fig. 4 . These
results indicate that cytoskeletal integrity is not re-
quired for phosphorylation of MARCKS by activated
PKC, and that the influence of CD and STS on basal
Fig. 4. Effects of TPA and staurosporine on phosphorylation of
MARCKS in control and cytochalasin D-treated C6 glioma cells.
w32 xCells were prelabelled with P P for 3 h, then cytochalasin Di
 .10 mM or carrier alone was added to dishes for 1 h. For the
final 15 min of incubation, 200 nM TPA or 200 nM STS " as
.indicated was added. Soluble and membrane proteins were ob-
tained by sequential extraction with digitonin followed by Triton
X-100. Samples were heated at 808C for 10 min and heat-stable
proteins were precipitated with trichloroacetic acid prior to sepa-
ration by SDS-PAGE and autoradiography. The migration of
 .MARCKS M is indicated.
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MARCKS distribution and enhanced translocation
.by TPA in the case of CD is not due to additional
changes in its phosphorylation state.
3.3. PKCa translocation is independent of cyto-
skeletal integrity in C6 glioma cells
To further explore how F-actin disruption by CD
might influence TPA-induced translocation of MAR-
CKS, we examined directly whether cytoskeletal dis-
ruption could interfere with translocation to the mem-
brane of PKCa , a prominent isoform in C6 cells
w x34,35 that has been implicated in the function of
w x  .MARCKS 36,37 . As shown in Fig. 3 lower panel ,
most of the PKCa immunoreactivity was found in
the cytosolic fraction under basal conditions 39"2%
.in the membrane fraction; Table 1 . As expected,
treatment with 200 nM TPA for 15 min resulted in
Fig. 5. Effects of trifluoperazine and TPA on translocation and
phosphorylation of MARCKS in C6 glioma cells. Panel A:
confluent cells were treated with 200 nM TPA, 50 mM TFP or
 .200 nM STS " as indicated for 15 min prior to protein
extraction and quantitation of membrane associated MARCKS by
immunoblotting as described in Table 1. Panel B: cells were
w32 xprelabelled with P P for 4 h and treated with TPA, TFP, ori
STS as above. Phosphorylated MARCKS was detected by SDS-
PAGE and autoradiography as described in Fig. 4, quantified by
densitometry, and expressed relative to untreated control samples.
The mean"S.D. of three separate experiments is shown.
Fig. 6. Individual and combined influence of inhibitors of PKC
activity, cytoskeletal assembly, and calmodulin binding on mem-
brane association of MARCKS in the presence and absence of
TPA. C6 glioma cells were pretreated 1 h with 10 mM CD,
 .andror 15 min with 200 nM STS, 1 mM calmidazolium CMZ ,
or 50 mM TFP prior to extraction and quantitation of membrane
 .associated MARCKS by immunoblotting. TPA 200 nM was
 .  .also present solid bars or absent white bars during the final 15
min incubation as indicated. Data are from several independent
experiments and show the percent change in membrane
 .MARCKS mean"S.D. or 1r2 range, ns2–8 in the treatment
 .groups relative to untreated cells control from that experiment;
51"3% of total MARCKS was membrane associated under
control conditions. nd, not determined.
substantial translocation of PKCa to the membrane
 .fraction 87"3% . Despite inhibiting TPA-stimu-
lated MARCKS phosphorylation and translocation,
STS had little effect on either the basal distribution of
PKCa or its translocation in response to TPA. More-
over, while the concentration of CD used here pro-
foundly disrupted the integrity of the cytoskeleton
and influenced the localization of MARCKS, it did
not interfere with the basal distribution of PKCa or
its behavior in response to TPA and STS.
3.4. Calmodulin antagonists and TPA act synergisti-
cally on MARCKS translocation
Calmodulin is another protein that reportedly inter-
acts with the central basic domain of MARCKS and
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w xinfluences its membrane association 9,23,38 . Thus,
we examined the effect of the calmodulin antagonist
 .trifluoperazine TFP on the distribution and phos-
phorylation of MARCKS and its response to PKC
activation. In contrast to CD, treatment of C6 glioma
cells with TFP had little effect on the basal distribu-
 .tion of MARCKS Fig. 5A . However, TPA-induced
translocation of MARCKS to the cytosol was
markedly enhanced when TFP was present: only 22%
of total MARCKS remained membrane associated in
the presence of both TFP and TPA, vs 41% with TPA
alone significantly different by Student-Newman-
.Keuls analysis, P-0.05 . Similar results were ob-
served with the more potent and specific calmodulin
w xantagonist calmidazolium 39 , indicating that the
effects of TFP are indeed due to inhibition of
 .calmodulin binding Fig. 6 . TFP and CD added
together had little effect on basal MARCKS distribu-
tion, and the response to TPA under these conditions
indicated that enhanced PKC-mediated translocation
 .by TFP and CD are not additive Fig. 6 .
As with CD, the synergistic effect of TFP on
TPA-induced translocation of MARCKS was not ac-
companied by a comparable change in its phosphory-
 .lation state Fig. 5B : although TFP alone slightly
 .increased phosphorylation of MARCKS 1.8-fold , it
had no further effect on the increase produced by
TPA. Interestingly, while STS effectively antago-
nized TPA-induced phosphorylation and translocation
 .of MARCKS Table 1 , it only partially reversed
 .these parameters when TFP was also present Fig. 5 .
4. Discussion
In the present investigation we have optimized a
simple and rapid cell permeabilization protocol which
allows us to measure small changes in membrane
association of MARCKS. Under the basal conditions
established for C6 glioma cells, MARCKS was ap-
proximately equally distributed between the soluble
digitonin and membrane fractions and TPA alone
produced only a modest translocation to the cytosol
despite a four-fold increase in phosphorylation. One
of the most important results we obtained is that
inhibition of either calmodulin binding or actin poly-
merization can potentiate the PKC-induced transloca-
tion of MARCKS, apparently without affecting fur-
ther the level of MARCKS phosphorylation. This
observation may resolve apparent discrepancies in the
literature about the relationship between MARCKS
phosphorylation and translocation. Although it is gen-
erally accepted that phosphorylation by PKC is the
dominant mechanism causing MARCKS redistribu-
w xtion from membrane to cytosol 16,19,20 , other stud-
ies have suggested a more complex relationship
w x23,24 . In some cell types, translocation does not
occur upon increased MARCKS phosphorylation
w x25,26 , and the two events can be temporally dissoci-
w xated in C6 glioma cells 26 . Our results confirm that
factors in addition to its phosphorylation state influ-
ence the membrane association of MARCKS in per-
meabilized cells.
While inhibitors of calmodulin binding and actin
polymerization were similar in their abilities to syner-
gistically enhance TPA-induced MARCKS transloca-
tion without altering its phosphorylation, differences
were also noted in the effects of these agents on the
 .properties of MARCKS see Fig. 6 . CD, but not TFP
or calmidazolium, increased basal association of
MARCKS with the membrane fraction, suggesting
that certain membrane components and F-actin might
compete with each other for the central basic effector
domain of MARCKS. F-actin is known to compete
with both calmodulin binding and PKC phosphoryla-
w xtion for this domain 14 , but direct evidence that
F-actin and membrane binding are competitive has
not been previously reported. As G-actin reportedly
w xdoes not interact with MARCKS 14 , actin filament
disruption might liberate the effector domain of
MARCKS for increased interaction with acidic lipids
in the membrane, thus providing an important ener-
getic contribution to the affinity of membrane interac-
w xtion already provided by the myristoyl group 9,21 .
In any case, our results suggest that F-actin does not
restrict MARCKS solubilization by tethering it to the
membrane or Triton X-100-resistant cytoskeletal frac-
tions under basal conditions.
Unlike cytochalasin D treatment, inhibition of en-
dogenous calmodulin with trifluoperazine or calmida-
zolium alone had little effect on the distribution of
MARCKS between soluble and membrane fractions.
As other studies have shown that saturating
Ca2qrcalmodulin levels do inhibit MARCKS interac-
w xtion with phospholipids 9,23,38 , our results might
suggest either that basal calmodulin binding was
( )D.N. Douglas et al.rBiochimica et Biophysica Acta 1356 1997 121–130 129
minimal under the permeabilization conditions used
 2q. 2qie. low Ca , or that Ca rcalmodulin binding
does not influence membrane affinity in a more
physiological cell model. However, it is also possible
that the modest increase in phosphorylated MARCKS
 .1.8 fold in the presence of TFP was sufficient to
counter a slight increase in membrane affinity upon
removal of calmodulin. Indeed, several reports indi-
cate that Ca2qrcalmodulin binding can inhibit phos-
w xphorylation of MARCKS by PKC 11–13,40 , and
this inhibition has recently been shown to be Ca2q-
w xdependent in C6 cells 40 , although MARCKS distri-
bution was not monitored in that study.
Cytoskeletal integrity does not appear to be essen-
tial for either TPA-stimulated translocation of PKCa
to the membrane or resulting phosphorylation of
MARCKS in C6 glioma cells. CD also had no effect
on bombesin-stimulated MARCKS phosphorylation
in Swiss 3T3 fibroblasts, whereas phosphorylation of
the focal adhesion site-associated tyrosine kinase
FAK w xp125 was completely blocked 41 , suggesting
that the effect of actin filament disruption on PKC
activity is substrate specific. Although STS blocked
both phosphorylation and translocation of MARCKS
in response to TPA, it had no affect on the transloca-
tion of PKCa to the membrane in either CD-treated
or untreated cells. The latter observation is not sur-
prising, as STS is reported to interact mainly with the
w xC-terminal kinase domain of PKC 42 , while the
N-terminal regulatory domain is responsible for
TPArdiacylglycerol, Ca2q, and phosphatidylserine-
dependent interaction with the membrane bilayer.
This investigation has provided evidence for
at least two distinct effects of staurosporine on
MARCKS localization in C6 cells. First, STS can
inhibit TPA-stimulated phosphorylation and translo-
cation of MARCKS. This is likely due to direct
inhibition of PKC activity, as indicated here and in
w xprevious studies with this cell type 32,43 . The sensi-
tivity to STS may be influenced by other factors: TFP
appears to render MARCKS phosphorylation and
translocation less sensitive to inhibition by STS. Sec-
ond, STS appears to have PKC-independent effects
on MARCKS distribution, as this inhibitor but not
.the more specific PKC inhibitor BIM increased
membrane association of MARCKS without altering
its basal phosphorylation. This could reflect a PKC-
independent disruption of the cytoskeleton by STS:
previous studies have noted that this inhibitor induces
w xreorganization of actin filaments in 3T3 cells 44 and
w xalteration of C6 glioma cell morphology 43,45 . We
have recently shown that STS can also stimulate
phospholipase D activity in a PKC-independent man-
w xner in C6 cells 32 , and that overexpression of
MARCKS imparts TPA stimulation of both phos-
w xphatidylcholine turnover 36 and phospholipase D
 .activity unpublished results in human SK-N-MC
neuroblastoma cells. The relationships between
MARCKS, the cytoskeleton, and phospholipase D are
currently under investigation.
In conclusion, calmodulin and F-actin exhibit dis-
tinct effects on membrane association of MARCKS,
and both act to modulate PKC-mediated changes in
its subcellular distribution. The influence of calmod-
ulin and F-actin appear to be at least partially inde-
pendent of changes in the phosphorylation state of
MARCKS. These data are consistent with previous
w xevidence in C6 cells 40 showing that MARCKS is
poised to respond to and coordinate temporally dis-
tinct Ca2q- and PKC-mediated signals as part of a
physiological role in regulating membrane-cyto-
skeletal interactions.
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